The overall ambition is to identify novel, more precise predictive and minimal residual disease biomarkers for response prediction to radiotherapy, conventional chemotherapy, and SMO inhibition in post-pubertal SHH medulloblastoma patients to inform the next generation of trials. Here, SMO is linked to medulloblastoma.